Stock code: 688166 Stock abbreviation: Borui Pharmaceutical

Borui Biopharmaceutical (Suzhou) Co., Ltd

Q3 2024 Report

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

The Board of Directors, the Board of Supervisors, the directors, supervisors and senior management of the Company guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or material omissions, and bear individual and joint legal liability.

The person in charge of the company, the person in charge of accounting and the person in charge of the accounting institution (accounting supervisor) shall ensure the truthfulness, accuracy and completeness of the financial information in the quarterly report.

Whether the third quarter financial statements are audited

□ Yes √ No

1. Key financial data

(i) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

From the beginning of the reporting period to the report

Items The current reporting period is the same as the previous year from the beginning of the year to the end of the reporting period compared with the previous year

Period increase and decrease change End of period Increase and decrease change in the same period

Dynamic amplitude (%) Kinetic amplitude (%)

Operating income 319,137,248.68 -2.52 976,825,695.67 6.77

Net profit attributable to shareholders of listed companies 71,044,018.70 -13.73 177,408,752.96 -7.50

Deductions attributable to shareholders of listed companies were not 68,389,623.86 -17.34 173,625,833.88 -7.50

Net profit from recurring gains or losses

Net cash flow from operating activities N/A N/A 119,589,702.03 21.01

Basic earnings per share (RMB/share) 0.17 -10.53 0.42 -6.67

Diluted earnings per share (RMB/share) 0.17 -10.53 0.42 -6.67

Weighted average return on equity (%) 2.94 decreased by 0.51 7.37 decreased by 0.91

Percentage points, percentage points

Total R&D investment 78,874,621.38 30.53 221,637,996.27 35.30

The ratio of R&D investment to operating income was 24.71, an increase of 6.25, and 22.69, an increase of 4.78

(%) percentage points percentage points

At the end of the reporting period

The end of the reporting period was the end of the previous year and the end of the previous year

Change in increment or decrease

Degree (%)

Total assets 4,878,532,811.80 5,031,831,375.92 -3.05

Owners attributable to shareholders of listed companies 2,352,381,122.67 2,368,615,404.00 -0.69

Rights

Note 1: "The reporting period" refers to the three-month period from the beginning of the quarter to the end of the quarter.

Note 2: The year-on-year change in operating income in the reporting period was mainly affected by the year-on-year decrease in technology revenue.

Note 3: The year-on-year change in net profit attributable to shareholders of the listed company during the reporting period was mainly due to the company's adherence to the "R&D-driven" strategy and the continuous increase in R&D investment in BGM0504 injections and other products. After calculation, after excluding the impact of R&D expenses of innovative drugs, the net profit attributable to shareholders of listed companies in the reporting period increased by 16.11% year-on-year.

Note 4: R&D investment in the current period is the sum of the expensed R&D expenses and capitalized R&D expenditures in the current period.

(ii) Items and amounts of non-recurring gains and losses

√ Applicable □ Not applicable

Unit: Yuan Currency: RMB

Non-recurring profit and loss items Amount for the current period Beginning of the year to report Description

Closing amount

Gains and losses on disposal of illiquid assets, including -15,527.85 -23,511.16 of the provision for impairment of assets

Reversal part

Government subsidies included in the current profit or loss, but closely related to the company's normal business operations

1,184,400.43 6,143,330.43

Except for government grants that have a sustained impact on the company's profit or loss

In addition to the effective hedging business related to the normal operation of the company,

The fair value of financial assets and financial liabilities held by non-financial enterprises was 1,782,431.54 -1,464,172.83

Gains and losses on changes and gains and losses on disposal of financial assets and financial liabilities

Capital occupation fees charged to non-financial enterprises through profit or loss for the period 213,078.08

Other non-operating income and expenses other than the above items -168,064.98 -251,059.22

Less: Income tax impact 111,383.46 817,391.84

Impact of minority interests (after tax) 17,460.84 17,354.38

Total 2,654,394.84 3,782,919.08

The reasons should be explained for the company to identify the items not listed in the Explanatory Announcement No. 1 on Information Disclosure of Companies Offering Securities to the Public as non-recurring profit and loss items and the amount is significant, and the non-recurring profit and loss items listed in the Explanatory Announcement on Information Disclosure of Companies Offering Securities to the Public No. 1 - Extraordinary Profit and Loss as recurring profit and loss, the reasons should be explained.

√ Applicable □ Not applicable

Unit: Yuan Currency: RMB

The item involves the amount of money reason

Other income 750,000.00 Asset-related government grants

Other income 3,919,816.34 Advanced manufacturing value-added tax deduction

Other income 161,548.58 tax refund

(3) The circumstances and reasons for changes in the main accounting data and financial indicators

√ Applicable □ Not applicable

Project Name Percentage of Change (%) Main Reasons

Total R&D investment_ 30.53 The main reason is that the company adheres to the "R&D-driven" strategy,

Total R&D investment_ From the beginning of the year to the end of the reporting period, 35.30 BGM0504 of innovative drugs and inhaled preparations such as injections

Caused by the continuous increase in R&D investment

2. Shareholder information

(1) The total number of ordinary shareholders and the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top 10 shareholders

Unit: shares

Voting rights were restored at the end of the reporting period

The total number of preferred shareholders out of the total number of common shareholders at the end of the reporting period was 10,597 and 0

(if any)

Shareholdings of the top 10 shareholders (excluding shares lent through refinancing)

Includes staking, tokens

Holding refinancing or freezing situations

Shareholding limited borrowing

Name of Shareholder Shareholder Number of Shares Proportion Selling Shares Shares

Quality (%) of shares

Number of copies, Restricted Form, Quantity

The amount of shares

quantity

Yuan Jiandong from 113,535,123 26.87 0 0 N/A 0

Ran

Suzhou Borui Xinwen Management Consulting Partnership Other 26,801,844 6.34 0 0 None 0

(Limited Partnership)

Zhong Weifang Territory from 22,543,669 5.34 0 0 None 0

Ran

Advanced Manufacturing Industry Investment Fund (Limited Partnership) Other 18,612,863 4.41 0 0 Not applicable

know

Bank of China Limited - China Merchants Advantage Other 10,500,000 2.49 0 0 Not applicable

Enterprises flexibly allocate hybrid securities investment funds Know

Beijing Sequoia Kunde Investment Management Center (limited

Partnership)-Ningbo Meishan Bonded Port Area Sequoia Zhi Other 4,230,163 1.00 0 0 Know Not applicable

Sheng Equity Investment Partnership (Limited Partnership)

Hong Kong Securities Clearing Company Limited Other 4,199,956 0.99 0 0 Not applicable

know

Industrial and Commercial Bank of China Co., Ltd

SSE STAR Market 100 ETF Other 3,445,629 0.82 0 0 Know Not applicable

Securities investment funds

Sun Jianlei from 3,343,358 0.79 0 0 Not applicable

But people know

China Merchants Bank Co., Ltd. - CSI South

1000 ETF Securities Investment Base Other 3,342,981 0.79 0 0 Know Not applicable

gold

Shareholdings of the top 10 unrestricted shareholders (excluding shares lent through refinancing)

Name of shareholder Holding unrestricted tradable shares Type and number of shares

The number of shares in the class of shares

Yuan Jiandong 113,535,123 RMB ordinary shares 113,535,123

Suzhou Borui Xinwen Management Consulting Partnership 26,801,844 RMB ordinary shares 26,801,844

(Limited Partnership)

Zhong Weifang 22,543,669 RMB ordinary shares 22,543,669

Advanced Manufacturing Industry Investment Fund (Limited Partnership) 18,612,863 RMB ordinary shares 18,612,863

Bank of China Co., Ltd. - China Merchants Advantage 10,500,000 RMB ordinary shares 10,500,000

Enterprises flexibly allocate hybrid securities investment funds

Beijing Sequoia Kunde Investment Management Center (Limited

Partnership) - Ningbo Meishan Bonded Port Zone Sequoia Zhi 4,230,163 RMB ordinary shares 4,230,163

Sheng Equity Investment Partnership (Limited Partnership)

Hong Kong Securities Clearing Company Limited 4,199,956 RMB ordinary shares 4,199,956

Industrial and Commercial Bank of China Co., Ltd. - Bosera

SSE STAR Market 100 ETF 3,445,629 RMB ordinary shares 3,445,629

Securities investment funds

Sun Jianlei 3,343,358 RMB ordinary shares 3,343,358

China Merchants Bank Co., Ltd. - CSI

1000 ETF Securities Investment Base 3,342,981 RMB ordinary shares 3,342,981

gold

Yuan Jiandong holds 26.87% of the company's shares; Zhong Weifang holds 5.34% of the company's shares

and holds the company's shareholder Suzhou Borui Xinwen Management Consulting Partnership (limited contract

49.72% interest in the above-mentioned shareholders who are affiliated or acting in concert and act as the executive partner; The company's shareholder Suzhou Borui

Ming Xinwen Management Consulting Partnership (Limited Partnership) holds 6.34% of the company's shares.

Zhong Weifang and Yuan Jiandong are mother-son relationships and are the actual controllers of the company.

The Company does not know whether the other shareholders are related or acting in concert.

Top 10 shareholders and top 10 unrestricted shareholders

Participation in margin trading and refinancing business is not applicable

Ming (if any)

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participate in the lending of shares in the refinancing business

√ Applicable □ Not applicable

Unit: shares

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participate in the lending of shares in the refinancing business

Ordinary account at the beginning of the period, refinancing at the beginning of the credit period Ordinary account at the end of the period, refinancing at the end of the credit period

Holding shares with an account and not returning them with an account holding a borrowed share and not yet

Shareholder's name (full name) Returned

Total Quantity Proportional Quantity Proportion Quantity Total Proportion Quantity Proportion

(%) Total (%) Total (%)

Industrial and Commercial Bank of China shares

Ltd. - Bosera on

CSI STAR 100 Trading 2,978,089 0.70 641,100 0.15 3,445,629 0.82 0 0.00

open-ended index securities

investment fund

China Merchants Bank Co., Ltd

Company - CSI 374,753 0.09 77,300 0.02 3,342,981 0.79 0 0.00

1000 transactional open-ended

Index Securities Investment Funds

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed compared to the previous period due to the refinancing loan/repayment

√ Applicable □ Not applicable

Unit: shares

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to the refinancing, lending/repayment

This newspaper at the end of the period refinancing lending at the end of the period shareholders ordinary account, credit

Shares that have not been returned to the account and refinancing loans

Name of Shareholder (Full Name) New/Quantity The number of shares that have not yet been returned

Exit Quantity Proportion Total Quantity Proportion

Total (%) (%)

Industrial and Commercial Bank of China Co., Ltd

SSE 100 Exchange-traded Open-ended Index Securities Added 0 0.00 3,445,629 0.82

investment fund

China Merchants Bank Co., Ltd.-CSI Added 0 0.00 3,342,981 0.79

1000 ETF ETF

3. Other reminders

Other important information about the company's operations in the reporting period that investors need to be reminded of

√ Applicable □ Not applicable

1. In terms of major R&D projects, the R&D progress of major products as of the disclosure date of this report is as follows:

(1) The phase II clinical trials of BGM0504 injection for weight loss and type 2 diabetes treatment in China have met the expected goals

Among them, the indication for weight loss has obtained the ethics approval for phase III clinical trial, and the first subject has been enrolled, and the phase III clinical study needs to be completed in the follow-up, and can only be produced and marketed after being reviewed and approved by the State Food and Drug Administration; The phase III communication for hypoglycemic indications has been replied by the CDE and agreed to carry out phase III clinical trials, and the phase III clinical trial can only be carried out after obtaining the clinical trial ethics approval from the hospital.

(2) The indication for weight loss of BGM0504 injection has been approved for IND in United States, and the first subject has been enrolled.

(3) Oral BGM0504 is currently in the preclinical research stage.

(4) BGC0228 for injection has completed the phase I clinical trial.

On the generic drug side, the R&D progress of major products as of the disclosure date of this report is as follows:

(1) Budesonide suspension for inhalation has been declared in China.

(2) Tiotropium Odaterol Inhalation Spray has passed the BE test (Bioequivalence Test), Tiotropium Bromide Inhalation Spray has passed the BE test (Bioequivalence Test), and Tiotropium Bromide Inhalation Powder Aerosol has completed the pilot test.

(3) The clinical trial application for salmeterol ticasone inhalation powder aerosol has been approved, and the first subject has been enrolled.

(4) The BE test (bioequivalence test) has been completed for carboxymaltose iron injection.

2. In terms of domestic registration, in the third quarter of 2024, salmeterol ticasone inhalation powder aerosol, gallium [68Ga]PSMA-0057 injection, and lutetium [177Lu]PSMA-0057 injection obtained the drug clinical trial approval notice.

In terms of international registration, in the third quarter of 2024, the New Drug Application (IND) for the indication of weight loss for BGM0504 injection was approved in United States, fondaparinux injection was approved in Indonesia, eribulin mesylate API passed the United States DMF technical review and was approved in Japan, and anidulafungin API and fondaparinux were approved in India. BGM0504 Injection submitted IND application for hypoglycemic indication to Indonesia, DABAVANCIN hydrochloride API submitted DMF to Canada, vorcidiosporine API and saxagliptin intermediate submitted DMF to United States, and sugammadex sodium API submitted DMF to Australia.

3. In terms of intellectual property rights, in the third quarter of 2024, the company submitted 10 new domestic patent applications and obtained new domestic patent authorization

9 cases, and 1 new foreign patent application. As of the end of September 2024, the company has applied for a total of 490 patents, including inventions

434 pieces; It has a total of 261 valid patents, including 220 invention patents, and has been deployed in United States, Japan, Canada, Europe,

Korea and other countries and regions.

4. As of the end of September 2024, the company's construction projects are as follows:

Taixing API and Preparation Production Base (Phase II), (1) has completed the acceptance of all single buildings and fire protection; (2) The trial production has passed the expert signature opinion; (3) The opinions of environmental protection experts have been issued and are being rectified.

Suzhou Inhaler and Other Chemical Preparation Production Base and Biomedical R&D Center Project (Phase I), (1) The structure of plant (1) and plant (2) has been capped, the secondary structure has been completed, and the installation of doors and windows has been completed; The structure of the R&D building, dangerous goods warehouse and sewage station has been capped, and the secondary structure has been completed; In the construction of the foundation column of the overhead corridor 1, the overall completion is 5%; The accident pool structure is complete, and the overall is 80% complete; Curtain wall construction is 90% complete; (2) The mechanical and electrical construction of the plant (1) has been completed, and the mechanical and electrical construction of the first, fifth, sixth and seventh floors of the plant (2) has been completed by 90%.

The new project (phase II) of Suzhou inhaler and other chemical preparation production base and biomedical R&D center, the mechanical and electrical installation and commissioning of the soft mist workshop was completed.

In the construction project of innovative drug preparation and raw material production base (phase I), the enclosure structure of Suzhou preparation production base has been completed, the main mechanical and electrical materials have been entered, and the construction has been completed by 30%; At present, the maintenance structure of Taixing API production base has been completed, and the main mechanical and electrical materials have entered the site. Quarterly financial statements

(i) Type of audit opinion

□ Applicable √ Not applicable

(ii) Financial statements

Consolidated balance sheet

September 30, 2024

Preparation unit: Borui Biopharmaceutical (Suzhou) Co., Ltd

Unit: Yuan Currency: RMB Audit Type: Unaudited

Project September 30, 2024 December 31, 2023

Liquid asset:

Monetary funds 505,357,865.57 998,045,685.92

Settlement Provisions

Lending funds

Tradable financial assets 0.00 50,617,054.79

Derivative financial assets

Notes receivable 0.00 2,365,608.40

Accounts receivable 369,536,455.40 282,978,228.31

Receivables financing 2,253,603.74 23,531,508.68

Prepayments 107,954,668.17 52,449,158.94

Premiums receivable

Reinsurance receivables

Reserve for reinsurance contracts receivable

Other receivables 3,032,209.50 19,914,098.86

Where: Interest receivable 0.00 0.00

Dividends receivable 0.00 0.00

Buy and sell back financial assets

Inventories 339,742,470.71 344,627,860.71

Where: data resources

Contract Assets

Assets held for sale

Non-current assets that mature within one year

Other current assets 54,640,056.19 65,209,123.12

Total current assets 1,382,517,329.28 1,839,738,327.73

Non-current assets:

Loans and advances are issued

Debt investment

Other debt investments

Long-term receivables

Long-term equity investment 39,325,778.89 43,490,102.12

Investment in other equity instruments 85,453,039.67 110,699,517.63

Other non-current financial assets 58,945,678.24 79,983,320.06

Investment properties 60,286,957.93 62,454,445.65

Fixed assets 1,075,681,761.85 718,121,508.52

Construction in progress 1,621,450,042.69 1,736,234,888.16

Productive biological assets

Oil and gas assets

Right-of-use assets 23,513,017.43 34,158,495.11

Intangible assets 90,827,095.40 93,664,771.45

Where: data resources

Development expenditure 9,258,962.26 0.00

Where: data resources

Goodwill 7,500,000.00 7,500,000.00

Long-term amortized expenses 28,604,665.65 30,184,563.96

Deferred income tax assets 56,071,439.09 42,280,888.95

Other non-current assets 339,097,043.42 233,320,546.58

Total non-current assets 3,496,015,482.52 3,192,093,048.19

Total assets 4,878,532,811.80 5,031,831,375.92

Current Liabilities:

Short-term borrowings 122,138,205.34 156,873,727.68

Borrowing from the Central Bank

Split funds

Transactional financial liabilities 382,600.00 2,234,420.00

Derivative financial liabilities

Notes payable 39,775,702.02 40,000,000.00

Accounts payable 174,066,301.39 188,177,443.12

Advance Receipts

Contract liabilities 28,549,329.77 24,003,258.96

Proceeds from the sale and repurchase of financial assets

Absorption of deposits and interbank deposits

Acting as an agent for the purchase and sale of securities

Acting as an agent for underwriting securities

Employee compensation payable 14,637,196.78 49,126,635.80

Taxes payable 15,972,449.15 17,897,050.18

Other accounts payable 9,341,695.56 9,821,168.73

Where: Interest payable 0.00 0.00

Dividend payable 0.00 0.00

Fees and commissions payable

Reinsurance payable

Liabilities held for sale

Non-current liabilities due within one year 463,613,234.30 414,031,035.60

Other current liabilities 17,007,915.47 20,082,776.21

Total current liabilities 885,484,629.78 922,247,516.28

Non-current liabilities:

Reserve for insurance contracts

Long-term borrowings 1,104,249,061.43 1,184,658,415.12

Bonds payable 448,356,214.47 430,260,881.21

Among them: preferred shares

Perpetual bonds

Lease liabilities 20,053,243.33 21,011,016.38

Long-term payables 69,550,000.00 46,820,000.00

Long-term payable employee compensation

Projected liabilities

Deferred income 8,500,000.00 9,250,000.00

Deferred tax liabilities

Other non-current liabilities

Total non-current liabilities 1,650,708,519.23 1,692,000,312.71

Total liabilities 2,536,193,149.01 2,614,247,828.99

Owner's Equity (or Shareholders' Equity):

Paid-up capital (or share capital) 422,466,561.00 422,466,533.00

Other equity instruments 75,639,635.72 75,639,798.41

Among them: preferred shares

Perpetual bonds

Capital reserve 949,381,893.93 1,057,132,047.12

Less: Treasury shares 10,009,948.64 0.00

Other comprehensive income -119,642,893.27 -84,281,994.28

Special reserves

Surplus reserve 67,219,535.13 67,219,535.13

General Risk Provisions

Undistributed profit 967,326,338.80 830,439,484.62

Equity attributable to owners of the parent company (or shareholders' rights 2,352,381,122.67 2,368,615,404.00

benefit) total

Minority interests -10,041,459.88 48,968,142.93

Total owners' equity (or shareholders' equity) 2,342,339,662.79 2,417,583,546.93

Liabilities and owners' equity (or shareholders' rights 4,878,532,811.80 5,031,831,375.92

benefit) total

The person in charge of the company: Yuan Jiandong The person in charge of accounting: Zou Yuanlai The person in charge of the accounting institution: Liu Fang

Consolidated income statement

January-September 2024

Preparation unit: Borui Biopharmaceutical (Suzhou) Co., Ltd

Unit: Yuan Currency: RMB Audit Type: Unaudited

Project Q3 2024 Q3 2023

(January-September) (January-September)

1. Total operating income 976,825,695.67 914,877,843.44

Among them: operating income 976,825,695.67 914,877,843.44

Interest income

Premiums earned

Fee and commission income

2. Total operating costs 798,339,394.77 699,599,219.95

Among them: operating costs 410,241,469.76 378,939,159.77

Interest expense

Handling fees and commission expenses

Surrender Benefit

Net payout expense

Draw down the net amount of insurance liability reserves

Policy dividend payouts

Reinsurance costs

Taxes and surcharges 5,066,165.95 4,420,583.31

Selling expenses 56,240,619.67 45,103,971.42

Administrative expenses 84,725,762.70 83,108,544.28

R&D expenses 212,379,034.01 163,815,024.16

Financial expenses 29,686,342.68 24,211,937.01

Including: interest expense 39,583,215.14 33,568,259.32

Interest income 8,787,032.44 10,398,097.47

Add: Other income 10,974,695.35 5,654,571.70

Investment income (loss is listed with "-") -9,634,825.62 -8,237,797.91

Among them: investment income on associates and joint ventures -7,160,973.23 -7,498,641.22

Termination of financial assets measured at amortized cost

Recognize the earnings

Exchange gain (loss is indicated with a "-")

Net Exposure Hedging Gain (Losses are indicated with a "-" sign)

Fair value change gain (loss) is marked with "-" 1,009,679.56 255,430.60

columns)

Credit impairment loss (loss is listed with "-") -7,251,559.45 -6,882,150.46

Asset impairment loss (loss is listed with "-") -5,233,377.22 -8,112,220.14

Gain on disposal of assets (loss is indicated with a "-")

3. Operating profit (loss is listed with "-") 168,350,913.52 197,956,457.28

Add: Non-operating income 35,088.06 194,609.59

Less: Non-operating expenses 309,658.44 462,778.35

4. Total profit (total loss is listed with "-") 168,076,343.14 197,688,288.52

Less: Income tax expense 21,318,816.30 20,947,593.65

5. Net profit (net loss is listed with "-") 146,757,526.84 176,740,694.87

(1) Classification according to business continuity

1. Net profit from continuing operations (net loss is listed with "-") 146,757,526.84 176,740,694.87

2. Net profit from discontinued operations (net loss is listed with "-")

(2) Classification according to ownership ownership

1. Net profit attributable to shareholders of the parent company (net loss in the form of 177,408,752.96 191,790,741.75

"-" sign)

2. Minority shareholders' profit and loss (net loss is listed with "-") -30,651,226.12 -15,050,046.88

6. Net after-tax of other comprehensive income -35,070,709.12 -4,907,097.88

(1) Tax on other comprehensive income attributable to owners of the parent company -35,070,709.12 -4,907,097.88

Net after

1. Other comprehensive income that cannot be reclassified into profit or loss -35,360,898.99 -5,325,099.53

(1) Remeasure the change in the defined benefit plan

(2) Other comprehensive income that cannot be converted into profit or loss under the equity method

(3) Changes in fair value of investments in other equity instruments -35,360,898.99 -5,325,099.53

(4) Changes in the fair value of the enterprise's own credit risk

2. Other comprehensive income reclassified into profit or loss 290,189.87 418,001.65

(1) Other comprehensive income from transferable gains or losses under the equity method

(2) Changes in the fair value of other debt investments

(3) Financial assets are reclassified into other comprehensive income

amount

(4) Other credit impairment provisions for debt investments

(5) Cash flow hedging reserves

(6) Translation difference of foreign currency financial statements 290,189.87 418,001.65

(7) Miscellaneous

(2) After-tax of other comprehensive income attributable to minority shareholders

Net

7. Total comprehensive income 111,686,817.72 171,833,596.99

(1) Total comprehensive income attributable to owners of the parent company 142,338,043.84 186,883,643.87

(2) Total comprehensive income attributable to minority shareholders -30,651,226.12 -15,050,046.88

8. Earnings per share:

(1) Basic earnings per share (RMB/share) 0.42 0.45

(2) Diluted earnings per share (RMB/share) 0.42 0.45

In the event of a business combination under the same control in the current period, the net profit realized by the merged party before the merger was 0 yuan, and the net profit realized by the merged party in the previous period was 0 yuan.

The person in charge of the company: Yuan Jiandong The person in charge of accounting: Zou Yuanlai The person in charge of the accounting institution: Liu Fang

Consolidated Statement of Cash Flows

January-September 2024

Preparation unit: Borui Biopharmaceutical (Suzhou) Co., Ltd

Unit: Yuan Currency: RMB Audit Type: Unaudited

Project Q3 2024 Q3 2023

(January-September) (January-September)

1. Cash flow from operating activities:

Cash received from the sale of goods and the provision of services 813,792,937.47 681,771,316.43

Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

Net increase in borrowing and lending to other financial institutions

Cash received from the premium of the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders' savings and investments

Cash for interest, fees and commissions

Net increase in borrowed funds

Net increase in funds from repurchase operations

Net cash received from agents to buy or sell securities

Tax refunds received 48,813,455.71 32,538,299.66

Other cash received related to operating activities 41,416,883.97 54,436,416.86

Subtotal cash inflow from operating activities 904,023,277.15 768,746,032.95

Cash for the purchase of goods and payment for services 286,207,185.98 211,512,156.74

Net increase in customer loans and advances

Net increase in deposits with central banks and interbank funds

Cash payment of the original insurance contract indemnity

Net increase in funds withdrawn

Cash for interest, fees and commissions

Cash to pay policy dividends

Cash paid to and on behalf of employees 204,656,001.24 187,943,137.62

Taxes paid 67,140,777.52 55,141,135.42

Other cash payments related to operating activities 226,429,610.38 215,321,153.46

Subtotal cash outflow from operating activities 784,433,575.12 669,917,583.24

Net cash flow from operating activities 119,589,702.03 98,828,449.71

2. Cash flow from investment activities:

Cash received from recovery of investments 61,749,840.21 50,000,000.00

Cash received from investment income 33,041.28 2,095,627.55

Disposal of fixed assets, intangible assets and other long-term assets 0.00 104,068.00

Net cash returned

Net cash received from disposal subsidiaries and other business units

Other cash received related to investing activities 36,498,977.60 0.00

Subtotal cash inflow from investing activities 98,281,859.09 52,199,695.55

Acquisition and construction of fixed assets, intangible assets and other long-term assets 251,051,326.55 300,316,967.31

Cash paid

Cash paid for investments 272,103,670.16 115,601,896.00

Net increase in pledged loans

Net cash payments from subsidiaries and other business units

Other cash payments related to investing activities 0.00 3,868,540.20

Subtotal cash outflow from investing activities 523,154,996.71 419,787,403.51

Net cash flow from investing activities -424,873,137.62 -367,587,707.96

3. Cash flow from financing activities:

Cash received from investment 0.00 60,000,000.00

Among them: cash received by subsidiaries from absorbing minority shareholders' investments 0.00 60,000,000.00

Cash received from borrowings 595,962,819.75 559,275,770.81

Other cash received in connection with fund-raising activities

Subtotal cash inflows from financing activities 595,962,819.75 619,275,770.81

Cash paid for debt repayment 627,876,477.53 447,115,551.12

Cash paid for dividends, profits or interest payments 118,858,800.88 100,513,983.05

Among them: dividends and profits paid by subsidiaries to minority shareholders

Other cash disbursements related to fund-raising activities 22,994,592.31 4,962,463.75

Subtotal cash outflow from financing activities 769,729,870.72 552,591,997.92

Net cash flow from financing activities -173,767,050.97 66,683,772.89

IV. Impact of exchange rate changes on cash and cash equivalents 1,333,672.34 -3,808,594.82

5. Net increase in cash and cash equivalents -477,716,814.22 -205,884,080.18

Add: Opening cash and cash equivalents balance 971,040,794.23 1,151,735,010.55

6. Balance of cash and cash equivalents at the end of the period 493,323,980.01 945,850,930.37

The person in charge of the company: Yuan Jiandong The person in charge of accounting: Zou Yuanlai The person in charge of the accounting institution: Liu Fang

The first implementation of new accounting standards or interpretations of standards from 2024 onwards involves adjustments to the financial statements at the beginning of the year in which they were first implemented

□ Applicable √ Not applicable

The announcement is hereby made.

Board of Directors of Borui Biopharmaceutical (Suzhou) Co., Ltd

October 29, 2024